Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8714652 | The Journal of Allergy and Clinical Immunology: In Practice | 2017 | 10 Pages |
Abstract
The ability to individualize therapies for NP is dependent on identifying clinical features or biomarkers of eosinophilia. However, with the exception of circulating eosinophilia, we could not identify a clinical feature or biomarker that robustly predicted the presence of tissue eosinophilia. Even more problematic, even the seeming “criterion standard” determination of tissue pathology was of limited value, as our cohort displayed a continuous spectrum of tissue eosinophil expression, making arbitrary any definitive cutoff distinguishing these conditions.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
John W. PhD, Anna R. MD, Delaney J. MD, James T. MS, Spencer C. MD, Larry MD,